Treatment Affordability

Inspired by a real patient.

ELIGARD® is one of the most affordable ADTs

ELIGARD has not had a price increase for over 10 years1*

Tolmar understands that cancer can bring financial stress along with emotional and physical challenges and is dedicated to making affordable treatment. With ELIGARD, you can feel more confident about the cost of treatment, which can help keep your out-of-pocket (OOP) burden as low as possible. 

*
Price refers to the Wholesale Acquisition Cost (WAC), standardized to a one-month supply. Actual out-of-pocket costs may vary based on insurance coverage and individual plan details.
ELIGARD has consistently had one of the lowest prices in the gonadotropin-releasing hormone (GnRH) market, helping make care more affordable1
Chart depicting costs for ELIGARD and other drugs from 2018-2025
The prices shown are based on the Wholesale Acquisition Cost (WAC) for a one-month supply. What you pay out-of-pocket will depend on your insurance plan and coverage.
Chart depicting costs for ELIGARD and other drugs from 2018-2025
Chart depicting costs for ELIGARD and other drugs from 2018-2025

Wholesale acquisition cost (WAC) is the price a company sells a drug to a wholesaler for, before the drug goes to the pharmacy for sale to the patient.

Discover how to navigate the financial aspects of cancer

Medicare Part D changed in 2025, potentially affecting costs for patients 

If you take oral cancer medications, you may face high out-of-pocket (OOP) costs. These treatments often come with significant co-pays or coinsurance—especially if your insurance plan uses a tiered prescription system.

While Medicare Part D now caps annual OOP costs at $2,000, you might still see higher monthly premiums or changes in your plan’s coverage—like fewer plan options or certain medications being excluded from formularies. These shifts can increase what you pay for treatment.2,9

Talk to your doctor about an ADT option that offers long-standing efficacy and stable pricing—ELIGARD is the market-leading therapy with over 20 years of proven results and has not increased its price in the last decade.

How rising cancer costs & inflation are affecting your care

You shouldn’t have to compromise your financial well-being for quality healthcare  

Cancer is one of the most expensive medical conditions to treat in the United States and continues to be a growing financial burden. It can be difficult to manage the cost of cancer care while also covering essentials like housing, utilities, transportation, and food.3 
National Cost of Cancer Care chart

As inflation pushes prices higher, ELIGARD holds steady1,6

When cancer care costs rise, you may face high out-of-pocket expenses that make it harder to keep up with treatments or medications.5

2020-2024 price change for major consumer price index
2020-2024 price change for major consumer price index

98M

Americans skipped treatment or cut spending on essentials to cover healthcare costs7

64%

of cancer patients experienced increased stress from medical debts and out-of-pocket costs8

You may be able to avoid the financial stress caused by treatment by considering a low-cost ADT like ELIGARD 

Financial assistance

You may be nervous about the financial aspects of being diagnosed with cancer, but there are many organizations dedicated to helping you with those costs. Speak with the organizations below to see what type of assistance they may be able to offer. You should also check with your doctor’s office to see if other assistance is available.
This list is provided for informational purposes only and does not indicate an endorsement or sponsorship.

BenefitsCheckUp®​

CFAC: Cancer Financial Assistance Coalition

CancerCare® Co-Payment Assistance Foundation

HealthWell Foundation®

Medicine Assistance Tool

Patient Advocate Foundation

Financial toxicity

Tolmar is dedicated to making affordable treatment with ELIGARD® a reality for prostate cancer patients. Many patients with cancer face some degree of financial hardship and illness-related money troubles. With ELIGARD, patients can feel confident in the affordability of treatment and that cost burden is kept as low as possible.

  • Consistently has been one of the lowest wholesale acquisition costs (WACs) in the GnRH market
  • No WAC increase in more than 10 years1

Understand financial toxicity and how to ease the burden of care

ADT, androgen deprivation therapy; WAC, wholesale acquisition cost.

References: 1. Data on file. Tolmar, Inc.; 2025. 2. KFF. 2020 Employer Health Benefits Survey. Accessed November 2024. https://www.kff.org/report-section/ehbs-2020-section-9-prescription-drug-benefits 3. National Institutes of Health. National Cancer Institute. Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ®)–Patient Version. Updated June 6, 2024. Accessed April 1, 2025. https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-pdq 4. Mariotto A, Enewold L, et al. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1304-1312. 5. Yabroff KR, et al. Cancer diagnosis and treatment in working-age adults: Implications for employment, health insurance coverage, and financial hardship in the United States. AC: Can Jrnl Clin. 2024;74(4)341-358. 6. Davidenko V, Sweitzer M. U.S. food prices rose by 23.6 percent from 2020 to 2024. USDA Economic Research Service. Published February 14, 2025. Accessed April 30, 2025. https://www.ers.usda.gov/data-products/chart-gallery/chart-detail?chartId=58350# 7. WestHealth/Gallup. Estimated 98 million Americans skipped treatments, cut back on food, gas or utilities to pay for healthcare. Published August 4, 2022. Accessed April 30, 2025. https://westhealth.org/news/estimated-98-million-americans-skipped-treatments-cut-back-on-food-gas-or-utilities-to-pay-for-healthcare/ 8. National Institutes of Health. National Cancer Institute. Financial Toxicity and Cancer Treatment (PDQ)-Health Professional Version. Updated May 29, 2024. Accessed April 30, 2025. https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-hp-pdq 9. Formularies CVS Health. 2017 Drug Trend Report. Published 2017. Accessed May 21, 2025. https://s2.q4cdn.com/447711729/files/doc_downloads/company_documents/2017-drug-trend-report.pdf

You are now leaving ELIGARD.com.

Are you sure you want to leave? 

You are now navigating to the healthcare provider site.

Are you a healthcare provider?

Skip to content